The vitamin D/CYP24A1 story in cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 3, 2010, Pages 213-224

  King, Amanda N ^a   Beer, David G ^b   Christensen, Paul J ^a   Simpson, Robert U ^a   Ramnath, Nithya ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cancer; CYP24A1; Prognosis; Vitamin D

Indexed keywords

1 HYDROXYMETHYL 16 ENE 24,24 DIFLUORO 25 HYDROXY 26,27 BIS HOMOVITAMIN D3; 22 OXACALCITRIOL; ALFACALCIDOL; AMIDE; CALCITRIOL; CALCITRIOL DERIVATIVE; COLECALCIFEROL DERIVATIVE; CYTOCHROME P450; ENZYME; GEMINI; GENISTEIN; IMIDAZOLE DERIVATIVE; KETOCONAZOLE; LIAROZOLE; N (2 (1H IMIDAZOL 1 YL) 2 PHENYLETHYL) 4 CHLOROBIPHENYL 4 CARBOXAMIDE; PARICALCITOL; QW 1624F2 2; SEOCALCITOL; UNCLASSIFIED DRUG; VID 400; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER TISSUE; COLON; COLON CANCER; CYP24A1 GENE; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SYNTHESIS; ESOPHAGUS CANCER; GENE; GENE EXPRESSION; GENE TARGETING; GENETIC POLYMORPHISM; HUMAN; LUNG CANCER; MEDICAL LITERATURE; NEOPLASM; NONHUMAN; OVARY CANCER; PROGNOSIS; PROSTATE CANCER; REVIEW; TRANSCRIPTION REGULATION; VITAMIN D METABOLISM;

EID: 77950829862     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009030213     Document Type: Review

References (137)

1. Kallioniemi, A.; Kallioniemi, O. P.; Piper, J.; Tanner, M.; Stokke, T.; Chen, L.; Smith, H. S.; Pinkel, D.; Gray, J. W.; Waldman, F. M. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc. Natl. Acad. Sci. USA, 1994, 91(6), 2156-2160
2. Evans, R. M., The steroid and thyroid hormone receptor superfamily. Science, 1988, 240(4854), 889-895
3. Bikle, D. D.; Pillai, S. Vitamin D, calcium, and epidermal differentiation. Endocr. Rev., 1993, 14(1), 3-19.
4. Reichel, H.; Koeffler, H. P.; Norman, A. W. The role of the vitamin D endocrine system in health and disease. N. Engl. J. Med., 1989, 320(15), 980-991 (Pubitemid 19101616)
5. Zhu, K.; Bruce, D.; Austin, N.; Devine, A.; Ebeling, P. R.; Prince, R. L. Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. J. Bone Miner. Res., 2008, 23(8), 1343-1348 (Pubitemid 352040190)
6. Beer, T. M.; Myrthue, A. Calcitriol in cancer treatment: from the lab to the clinic. Mol. Cancer Ther., 2004, 3(3), 373-381 (Pubitemid 39193713)
7. Plum, L.A.; DeLuce, H.F. The functional metabolism and molecular biology of vitamin D action. Clin. Rev. Bone Miner. Metab., 2009, 7, 20-41.
8. Hansen, C. M.; Hansen, D.; Holm, P. K.; Binderup, L. Vitamin D compounds exert anti-apoptotic effects in human osteosarcoma cells in vitro. J. Steroid Biochem. Mol. Biol., 2001, 77(1), 1-11. (Pubitemid 32455348)
9. Zittermann, A. Vitamin D in preventive medicine: are we ignoring the evidence? Br. J. Nutr., 2003, 89(5), 552-572 (Pubitemid 36592083)
10. DeLuca, H. F. Overview of general physiologic features and functions of vitamin D. Am. J. Clin. Nutr., 2004, 80(6 Suppl), 1689S-96S.
11. Bouillon, R.; Verlinden, L.; Eelen, G.; De Clercq, P.; Vandewalle, M.; Mathieu, C.; Verstuyf, A. Mechanisms for the selective action of Vitamin D analogs. J. Steroid Biochem. Mol. Biol., 2005, 97(1-2), 21-30. (Pubitemid 41546210)
12. Shaffer, P. L.; Gewirth, D. T. Structural basis of VDR-DNA interactions on direct repeat response elements. EMBO J., 2002, 21(9), 2242-2252
13. Issa, L. L.; Leong, G. M.; Sutherland, R. L.; Eisman, J. A. Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. J. Bone Miner. Res., 2002, 17 (5), 879-890 (Pubitemid 34441905)
14. Deeb, K. K.; Trump, D. L.; Johnson, C. S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer, 2007, 7(9), 684-700.
15. Eisman, J. A.; Barkla, D. H.; Tutton, P. J. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res., 1987, 47(1), 21-25
16. Nagpal, S.; Na, S.; Rathnachalam, R. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev., 2005, 26(5), 662-687 (Pubitemid 41127276)
17. Wang, Q. M.; Jones, J. B.; Studzinski, G. P. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res., 1996, 56(2), 264-267
18. McGuire, T. F.; Trump, D. L.; Johnson, C. S. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J. Biol. Chem., 2001, 276(28), 26365-26373 (Pubitemid 37412854)
19. Cheng, H. T.; Chen, J. Y.; Huang, Y. C.; Chang, H. C.; Hung, W. C. Functional role of VDR in the activation of p27Kip1 by the VDR/Sp1 complex. J. Cell Biochem., 2006, 98(6), 1450-1456
20. Hershberger, P. A.; Modzelewski, R. A.; Shurin, Z. R.; Rueger, R. M.; Trump, D. L.; Johnson, C. S. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res., 1999, 59(11), 2644-2649
21. Moffatt, K. A.; Johannes, W. U.; Miller, G. J. 1Alpha, 25-dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin. Cancer Res., 1999, 5(3), 695-703.
22. Koshizuka, K.; Koike, M.; Asou, H.; Cho, S. K.; Stephen, T.; Rude, R. K.; Binderup, L.; Uskokovic, M.; Koeffler, H. P. Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res. Treat., 1999, 53(2), 113-120
23. Hershberger, P. A.; McGuire, T. F.; Yu, W. D.; Zuhowski, E. G.; Schellens, J. H.; Egorin, M. J.; Trump, D. L.; Johnson, C. S. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol. Cancer Ther., 2002, 1(10), 821-829
24. Light, B. W.; Yu, W. D.; McElwain, M. C.; Russell, D. M.; Trump, D. L.; Johnson, C. S. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res., 1997, 57, (17), 3759-3764
25. McElwain, M.C.; Modzelewski, R.A.; Yu, W.D.; Russell, D.M.; Johnson, C.S. Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma. Am. J. Otolaryngol., 1997, 18(5), 293-298. Review.
26. Liu, M.; Lee, M. H.; Cohen, M.; Bommakanti, M.; Freedman, L. P., Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev., 1996, 10(2), 142-153
27. Haussler, M. R.; Whitfield, G. K.; Haussler, C. A.; Hsieh, J. C.; Thompson, P. D.; Selznick, S. H.; Dominguez, C. E.; Jurutka, P. W. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res., 1998, 13(3), 325-349
28. Sakaki, T.; Sawada, N.; Nonaka, Y.; Ohyama, Y.; Inouye, K. Metabolic studies using recombinant escherichia coli cells producing rat mitochondrial CYP24 CYP24 can convert 1alpha,25-dihydroxyvitamin D3 to calcitroic acid. Eur. J. Biochem., 1999, 262(1), 43-48 (Pubitemid 29242607)
29. Brenza, H. L.; DeLuca, H. F. Regulation of 25-hydroxyvitamin D3 1alpha-hydroxylase gene expression by parathyroid hormone and 1,25-dihydroxyvitamin D3. Arch. Biochem. Biophys., 2000, 381 (1), 143-152
30. St-Arnaud, R. Targeted inactivation of vitamin D hydroxylases in mice. Bone, 1999, 25(1), 127-129 (Pubitemid 29322076)
31. Annalora, A. J.; Bobrovnikov-Marjon, E.; Serda, R.; Pastuszyn, A.; Graham, S. E.; Marcus, C. B.; Omdahl, J. L. Hybrid homology modeling and mutational analysis of cytochrome P450C24A1 (CYP24A1) of the Vitamin D pathway: insights into substrate specificity and membrane bound structure-function. Arch. Biochem. Biophys., 2007, 460(2), 262-273
32. Holick, M. F. Vitamin D for health and in chronic kidney disease. Semin. Dial., 2005, 18(4), 266-275 (Pubitemid 41159576)
33. Rukin, N. J.; Strange, R. C. What are the frequency, distribution, and functional effects of vitamin D receptor polymorphisms as related to cancer risk? Nutr. Rev., 2007, 65 (8 Pt 2), S96-101.
34. Dong, L. M.; Ulrich, C. M.; Hsu, L.; Duggan, D. J.; Benitez, D. S.; White, E.; Slattery, M. L.; Farin, F. M.; Makar, K. W.; Carlson, C. S.; Caan, B. J.; Potter, J. D.; Peters, U. Vitamin D related genes, CYP24A1 and CYP27B1, and colon cancer risk. Cancer Epidemiol. Biomarkers Prev., 2009, 18(9), 2540-2548
35. Wong, H. L.; Seow, A.; Arakawa, K.; Lee, H. P.; Yu, M. C.; Ingles, S. A. Vitamin D receptor start codon polymorphism and colorectal cancer risk: effect modification by dietary calcium and fat in Singapore Chinese. Carcinogenesis, 2003, 24(6), 1091-1095
36. Slattery, M. L. Vitamin D receptor gene (VDR) associations with cancer. Nutr. Rev., 2007, 65(8 Pt 2), S102-4.
37. Muindi, J.R.; Nganga, A.; Engler, K.L.; Coignet, L.G.; Johnson, C.S.; Trump, D.L. CYP24 splicing variants are associated with different patterns constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines. 2007, J. Steroid Biochem. Mol. Biol., 103, 334-337.
38. Roff, A.; Wilson, R. T. A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expression. J. Steroid Biochem. Mol. Biol., 2008, 112(1-3), 47-54.
39. Prosser, D. E.; Jones, G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci., 2004, 29(12), 664-673 (Pubitemid 39491265)
40. Oyama, T.; Kagawa, N.; Kunugita, N.; Kitagawa, K.; Ogawa, M.; Yamaguchi, T.; Suzuki, R.; Kinaga, T.; Yashima, Y.; Ozaki, S.; Isse, T.; Kim, Y. D.; Kim, H.; Kawamoto, T. Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front. Biosci., 2004, 9, 1967-1976 (Pubitemid 38918646)
41. Masuda, S.; Prosser, D. E.; Guo, Y. D.; Kaufmann, M.; Jones, G. Generation of a homology model for the human cytochrome P450, CYP24A1, and the testing of putative substrate binding residues by site-directed mutagenesis and enzyme activity studies. Arch. Biochem. Biophys., 2007, 460(2), 177-191 (Pubitemid 46589391)
42. Gomaa, M. S.; Simons, C.; Brancale, A. Homology model of 1alpha,25-dihydroxyvitamin D3 24-hydroxylase cytochrome P450 24A1 (CYP24A1): active site architecture and ligand binding. J. Steroid Biochem. Mol. Biol., 2007, 104(1-2), 53-60. (Pubitemid 46412991)
43. Hasemann, C. A.; Kurumbail, R. G.; Boddupalli, S. S.; Peterson, J. A.; Deisenhofer, J. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure, 1995, 3(1), 41-62.
44. Nebert, D. W.; Russell, D. W. Clinical importance of the cytochromes P450. Lancet, 2002, 360(9340), 1155-1162
45. Nelson, D. R. Cytochrome P450 and the individuality of species. Arch. Biochem. Biophys., 1999, 369(1), 1-10.
46. Danielson, P. B.; Fogleman, J. C. Isolation and sequence analysis of cytochrome P450 12B1: the first mitochondrial insect P450 with homology to 1 alpha,25 dihydroxy-D3 24-hydroxylase. Insect. Biochem. Mol. Biol., 1997, 27(6), 595-604.
47. Yoshizawa, T.; Handa, Y.; Uematsu, Y.; Takeda, S.; Sekine, K.; Yoshihara, Y.; Kawakami, T.; Arioka, K.; Sato, H.; Uchiyama, Y.; Masushige, S.; Fukamizu, A.; Matsumoto, T.; Kato, S. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet, 1997, 16(4), 391-396 (Pubitemid 27323308)
48. Chung, I.; Karpf, A. R.; Muindi, J. R.; Conroy, J. M.; Nowak, N. J.; Johnson, C. S.; Trump, D. L. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. J. Biol. Chem., 2007, 282(12), 8704-8714
49. Novakovic, B.; Sibson, M.; Ng, H. K.; Manuelpillai, U.; Rakyan, V.; Down, T.; Beck, S.; Fournier, T.; Evain-Brion, D.; Dimitriadis, E.; Craig, J. M.; Morley, R.; Saffery, R. Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. J. Biol. Chem., 2009, 284(22), 14838-14848
50. Vaisanen, S.; Dunlop, T. W.; Sinkkonen, L.; Frank, C.; Carlberg, C. Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1alpha,25-Dihydroxyvitamin D3. J. Mol. Biol., 2005, 350(1), 65-77. (Pubitemid 40804732)
51. Yang, B. S.; Hauser, C. A.; Henkel, G.; Colman, M. S.; Van Beveren, C.; Stacey, K. J.; Hume, D. A.; Maki, R. A.; Ostrowski, M. C. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol. Cell Biol., 1996, 16(2), 538-547
52. Nutchey, B. K.; Kaplan, J. S.; Dwivedi, P. P.; Omdahl, J. L.; Ferrante, A.; May, B. K.; Hii, C. S. Molecular action of 1,25-dihydroxyvitamin D3 and phorbol ester on the activation of the rat cytochrome P450C24 (CYP24) promoter: role of MAP kinase activities and identification of an important transcription factor binding site. Biochem. J., 2005, 389(Pt 3), 753-762
53. Cui, M.; Klopot, A.; Jiang, Y.; Fleet, J. C. The effect of differentiation on 1,25 dihydroxyvitamin D-mediated gene expression in the enterocyte-like cell line, Caco-2. J. Cell Physiol., 2009, 218(1), 113-121
54. Dwivedi, P. P.; Hii, C. S.; Ferrante, A.; Tan, J.; Der, C. J.; Omdahl, J. L.; Morris, H. A.; May, B. K. Role of MAP kinases in the 1,25-dihydroxyvitamin D3-induced transactivation of the rat cytochrome P450C24 (CYP24) promoter. Specific functions for ERK1/ERK2 and ERK5. J. Biol. Chem., 2002, 277 (33), 29643-29653
55. Tolon, R. M.; Castillo, A. I.; Jimenez-Lara, A. M.; Aranda, A. Association with Ets-1 causes ligand- and AF2-independent activation of nuclear receptors. Mol. Cell Biol., 2000, 20(23), 8793-8802 (Pubitemid 32245912)
56. Komagata, S.; Nakajima, M.; Takagi, S.; Mohri, T.; Taniya, T.; Yokoi, T. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol. Pharmacol., 2009, 76(4), 702-709
57. Tokar, E. J.; Webber, M. M. Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. Clin. Exp. Metastasis., 2005, 22(3), 265-273
58. Anderson, M. G.; Nakane, M.; Ruan, X.; Kroeger, P. E.; Wu-Wong, J. R., Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother. Pharmacol., 2006, 57(2), 234-240 (Pubitemid 41779843)
59. Mimori, K.; Tanaka, Y.; Yoshinaga, K.; Masuda, T.; Yamashita, K.; Okamoto, M.; Inoue, H.; Mori, M. Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann. Oncol., 2004, 15 (2), 236-241 (Pubitemid 38262621)
60. Meyer, M. B.; Zella, L. A.; Nerenz, R. D.; Pike, J. W. Characterizing early events associated with the activation of target genes by 1,25-dihydroxyvitamin D3 in mouse kidney and intestine in vivo. J. Biol. Chem., 2007, 282(31), 22344-22352
61. Hansdottir, S.; Monick, M. M.; Hinde, S. L.; Lovan, N.; Look, D. C.; Hunninghake, G. W. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J. Immunol., 2008, 181(10), 7090-7099
62. Schuster, I.; Egger, H.; Astecker, N.; Herzig, G.; Schussler, M.; Vorisek, G. Selective inhibitors of CYP24: mechanistic tools to explore vitamin D metabolism in human keratinocytes. Steroids, 2001, 66(3-5), 451-462 (Pubitemid 32140922)
63. Gissel, T.; Rejnmark, L.; Mosekilde, L.; Vestergaard, P. Intake of vitamin D and risk of breast cancer - a meta-analysis. J. Steroid Biochem. Mol. Biol., 2008, 111, (3-5), 195-199
64. Garland, C. F.; Gorham, E. D.; Mohr, S. B.; Grant, W. B.; Giovannucci, E. L.; Lipkin, M.; Newmark, H.; Holick, M. F.; Garland, F. C. Vitamin D and prevention of breast cancer: pooled analysis. J. Steroid Biochem. Mol. Biol., 2007, 103(3-5), 708-711 (Pubitemid 46420519)
65. Gorham, E. D.; Garland, F. C.; Garland, C. F. Sunlight and breast cancer incidence in the USSR. Int. J. Epidemiol., 1990, 19(4), 820-824
66. Newmark, H. L. Vitamin D adequacy: a possible relationship to breast cancer. Adv. Exp. Med. Biol., 1994, 364, 109-114
67. Mawer, E. B.; Walls, J.; Howell, A.; Davies, M.; Ratcliffe, W. A.; Bundred, N. J. Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J. Clin. Endocrinol. Metab., 1997, 82(1), 118-122
68. Narvaez, C. J.; Welsh, J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J. Biol. Chem., 2001, 276(12), 9101-9107 (Pubitemid 37385490)
69. Swami, S.; Raghavachari, N.; Muller, U. R.; Bao, Y. P.; Feldman, D. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res. Treat., 2003, 80(1), 49-62. (Pubitemid 36851284)
70. Albertson, D. G.; Ylstra, B.; Segraves, R.; Collins, C.; Dairkee, S. H.; Kowbel, D.; Kuo, W. L.; Gray, J. W.; Pinkel, D. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet., 2000, 25(2), 144-146 (Pubitemid 30394982)
71. Garland, C. F.; Garland, F. C. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int. J. Epidemiol., 1980, 9 (3), 227-231
72. Garland, C. F.; Comstock, G. W.; Garland, F. C.; Helsing, K. J.; Shaw, E. K.; Gorham, E. D. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet, 1989, 2(8673), 1176-1178 (Pubitemid 19275448)
73. Bostick, R. M.; Potter, J. D.; Sellers, T. A.; McKenzie, D. R.; Kushi, L. H.; Folsom, A. R. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The Iowa Women's Health Study. Am. J. Epidemiol., 1993, 137(12), 1302-1317
74. Freedman, D. M.; Dosemeci, M.; McGlynn, K. Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup. Environ. Med., 2002, 59(4), 257-262
75. Niv, Y.; Sperber, A. D.; Figer, A.; Igael, D.; Shany, S.; Fraser, G.; Schwartz, B. In colorectal carcinoma patients, serum vitamin D levels vary according to stage of the carcinoma. Cancer, 1999, 86(3), 391-397 (Pubitemid 29347399)
76. Tangpricha, V.; Flanagan, J. N.; Whitlatch, L. W.; Tseng, C. C.; Chen, T. C.; Holt, P. R.; Lipkin, M. S.; Holick, M. F. 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet, 2001, 357(9269), 1673-1674 (Pubitemid 32568244)
77. Cross, H. S.; Nittke, T.; Peterlik, M. Modulation of vitamin D synthesis and catabolism in colorectal mucosa: a new target for cancer prevention. Anticancer Res., 2009, 29(9), 3705-3712
78. Bareis, P.; Bises, G.; Bischof, M. G.; Cross, H. S.; Peterlik, M. 25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. Biochem. Biophys. Res. Commun., 2001, 285(4), 1012-1017 (Pubitemid 32918038)
79. Cross, H. S.; Kallay, E.; Lechner, D.; Gerdenitsch, W.; Adlercreutz, H.; Armbrecht, H. J. Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. J. Nutr., 2004, 134 (5), 1207S-1212S.
80. Kallay, E.; Adlercreutz, H.; Farhan, H.; Lechner, D.; Bajna, E.; Gerdenitsch, W.; Campbell, M.; Cross, H. S. Phytoestrogens regulate vitamin D metabolism in the mouse colon: relevance for colon tumor prevention and therapy. J. Nutr., 2002, 132, (11 Suppl), 3490S-3493S.
81. Jemal, A.; Thun, M. J.; Ries, L. A.; Howe, H. L.; Weir, H. K.; Center, M. M.; Ward, E.; Wu, X. C.; Eheman, C.; Anderson, R.; Ajani, U. A.; Kohler, B.; Edwards, B. K. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J. Natl. Cancer Inst., 2008, 100(23), 1672-1694
82. Kilkkinen, A.; Knekt, P.; Heliovaara, M.; Rissanen, H.; Marniemi, J.; Hakulinen, T.; Aromaa, A., Vitamin D status and the risk of lung cancer: a cohort study in Finland. Cancer Epidemiol. Biomarkers Prev., 2008, 17(11), 3274-3278
83. Zhou, W.; Heist, R. S.; Liu, G.; Asomaning, K.; Neuberg, D. S.; Hollis, B. W.; Wain, J. C.; Lynch, T. J.; Giovannucci, E.; Su, L.; Christiani, D. C. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J. Clin. Oncol., 2007, 25(5), 479-485 (Pubitemid 350002952)
84. Zhou, W.; Suk, R.; Liu, G.; Park, S.; Neuberg, D. S.; Wain, J. C.; Lynch, T. J.; Giovannucci, E.; Christiani, D. C. Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol. Biomarkers Prev., 2005, 14(10), 2303-2309 (Pubitemid 41437829)
85. Higashimoto, Y.; Ohata, M.; Nishio, K.; Iwamoto, Y.; Fujimoto, H.; Uetani, K.; Suruda, T.; Nakamura, Y.; Funasako, M.; Saijo, N. 1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res., 1996, 16(5A), 2653-2659 (Pubitemid 26388231)
86. Young, M. R.; Montpetit, M.; Lozano, Y.; Djordjevic, A.; Devata, S.; Matthews, J. P.; Yedavalli, S.; Chejfec, G. Regulation of Lewis lung carcinoma invasion and metastasis by protein kinase A. Int. J. Cancer, 1995, 61(1), 104-109
87. Nakagawa, K.; Kawaura, A.; Kato, S.; Takeda, E.; Okano, T. 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis, 2005, 26(2), 429-440 (Pubitemid 40246565)
88. Beer, D. G.; Kardia, S. L.; Huang, C. C.; Giordano, T. J.; Levin, A. M.; Misek, D. E.; Lin, L.; Chen, G.; Gharib, T. G.; Thomas, D. G.; Lizyness, M. L.; Kuick, R.; Hayasaka, S.; Taylor, J. M.; Iannettoni, M. D.; Orringer, M. B.; Hanash, S. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med., 2002, 8(8), 816-824
89. Kim, B.; Lee, H. J.; Choi, H. Y.; Shin, Y.; Nam, S.; Seo, G.; Son, D. S.; Jo, J.; Kim, J.; Lee, J.; Kim, K.; Lee, S. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res., 2007, 67(15), 7431-7438 (Pubitemid 47206573)
90. Parise, R. A.; Egorin, M. J.; Kanterewicz, B.; Taimi, M.; Petkovich, M.; Lew, A. M.; Chuang, S. S.; Nichols, M.; El- Hefnawy, T.; Hershberger, P. A. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int. J. Cancer, 2006, 119(8), 1819-1828
91. Wong, M. P.; Fung, L. F.; Wang, E.; Chow, W. S.; Chiu, S. W.; Lam, W. K.; Ho, K. K.; Ma, E. S.; Wan, T. S.; Chung, L. P. Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. Cancer, 2003, 97(5), 1263-1270 (Pubitemid 36237313)
92. Schwartz, G. G.; Hulka, B. S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res., 1990, 10(5A), 1307-1311
93. Hanchette, C. L.; Schwartz, G. G. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer, 1992, 70(12), 2861-2869
94. Corder, E. H.; Guess, H. A.; Hulka, B. S.; Friedman, G. D.; Sadler, M.; Vollmer, R. T.; Lobaugh, B.; Drezner, M. K.; Vogelman, J. H.; Orentreich, N. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol. Biomarkers Prev., 1993, 2(5), 467-472
95. Braun, M. M.; Helzlsouer, K. J.; Hollis, B. W.; Comstock, G. W. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control., 1995, 6(3), 235-239
96. Gann, P. H.; Ma, J.; Hennekens, C. H.; Hollis, B. W.; Haddad, J. G.; Stampfer, M. J. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 1996, 5 (2), 121-126
97. Nomura, A. M.; Stemmermann, G. N.; Lee, J.; Kolonel, L. N.; Chen, T. C.; Turner, A.; Holick, M. F. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control., 1998, 9(4), 425-432
98. Skowronski, R. J.; Peehl, D. M.; Feldman, D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology, 1993, 132(5), 1952-1960 (Pubitemid 23133240)
99. Miller, G. J.; Stapleton, G. E.; Hedlund, T. E.; Moffat, K. A. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res., 1995, 1(9), 997-1003.
100. Young, M. V.; Schwartz, G. G.; Wang, L.; Jamieson, D. P.; Whitlatch, L. W.; Flanagan, J. N.; Lokeshwar, B. L.; Holick, M. F.; Chen, T. C. The prostate 25-hydroxyvitamin D-1 alphahydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis, 2004, 25(6), 967-971
101. Hershberger, P. A.; Yu, W. D.; Modzelewski, R. A.; Rueger, R. M.; Johnson, C. S.; Trump, D. L. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin. Cancer Res., 2001, 7(4), 1043-1051
102. Rohan, J. N.; Weigel, N. L. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology, 2009, 150 (5), 2046-2054
103. Dunlap, N.; Schwartz, G. G.; Eads, D.; Cramer, S. D.; Sherk, A. B.; John, V.; Koumenis, C. 1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br. J. Cancer, 2003, 89(4), 746-753 (Pubitemid 37076184)
104. Schwartz, G. G.; Wang, M. H.; Zang, M.; Singh, R. K.; Siegal, G. P. 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol. Biomarkers Prev., 1997, 6(9), 727-732 (Pubitemid 27427629)
105. Sung, V.; Feldman, D. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol. Cell Endocrinol., 2000, 164(1-2), 133-143 (Pubitemid 30665507)
106. Peehl, D. M.; Seto, E.; Hsu, J. Y.; Feldman, D. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J. Urol., 2002, 168(4 Pt 1), 1583-1588 (Pubitemid 35034194)
107. Lipworth, L.; Rossi, M.; McLaughlin, J. K.; Negri, E.; Talamini, R.; Levi, F.; Franceschi, S.; La Vecchia, C. Dietary vitamin D and cancers of the oral cavity and esophagus. Ann. Oncol., 2009, 20(9), 1576-1581
108. Lin, R.; Nagai, Y.; Sladek, R.; Bastien, Y.; Ho, J.; Petrecca, K.; Sotiropoulou, G.; Diamandis, E. P.; Hudson, T. J.; White, J. H. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol. Endocrinol., 2002, 16(6), 1243-1256
109. Lefkowitz, E. S.; Garland, C. F. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int. J. Epidemiol., 1994, 23(6), 1133-1136
110. Miettinen, S.; Ahonen, M. H.; Lou, Y. R.; Manninen, T.; Tuohimaa, P.; Syvala, H.; Ylikomi, T. Role of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells. Int. J. Cancer, 2004, 108(3), 367-373 (Pubitemid 37549601)
111. Lechner, D.; Bajna, E.; Adlercreutz, H.; Cross, H. S. Genistein and 17beta-estradiol, but not equol, regulate vitamin D synthesis in human colon and breast cancer cells. Anticancer Res., 2006, 26(4A), 2597-2603
112. Banerjee, S.; Li, Y.; Wang, Z.; Sarkar, F. H. Multi-targeted therapy of cancer by genistein. Cancer Lett., 2008, 269(2), 226-242
113. Farhan, H.; Wahala, K.; Cross, H. S. Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J. Steroid Biochem. Mol. Biol., 2003, 84(4), 423-429
114. Yee, S. W.; Simons, C. Synthesis and CYP24 inhibitory activity of 2-substituted-3,4-dihydro-2H-naphthalen-1-one (tetralone) derivatives. Bioorg. Med. Chem. Lett., 2004, 14(22), 5651-5654 (Pubitemid 39346362)
115. Ly, L. H.; Zhao, X. Y.; Holloway, L.; Feldman, D. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology, 1999, 140(5), 2071-2076 (Pubitemid 30636444)
116. Reinhardt, T. A.; Horst, R. L. Ketoconazole inhibits self-induced metabolism of 1,25-dihydroxyvitamin D3 and amplifies 1,25-dihydroxyvitamin D3 receptor up-regulation in rat osteosarcoma cells. Arch. Biochem. Biophys., 1989, 272(2), 459-465
117. Trump, D. L.; Muindi, J.; Fakih, M.; Yu, W. D.; Johnson, C. S. Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Res., 2006, 26(4A), 2551-2556
118. Alagbala, A. A.; Johnson, C. S.; Trump, D. L.; Posner, G. H.; Foster, B. A. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells. Oncology, 2006, 70(6), 483-492
119. Flanagan, J. N.; Zheng, S.; Chiang, K. C.; Kittaka, A.; Sakaki, T.; Nakabayashi, S.; Zhao, X.; Spanjaard, R. A.; Persons, K. S.; Mathieu, J. S.; Holick, M. F.; Chen, T. C. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha, 25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res., 2009, 29(9), 3547-3553
120. Hansen, C. M.; Mathiasen, I. S.; Binderup, L. The anti-proliferative and differentiation-inducing effects of vitamin D analogs are not determined by the binding affinity for the vitamin D receptor alone. J. Investig. Dermatol. Symp. Proc., 1996, 1(1), 44-48 (Pubitemid 126759340)
121. Akizawa, T.; Narukawa, N. Syndrome related to chronic dialysis. Ryoikibetsu Shokogun Shirizu, 2000, 29(Pt 4), 147-149
122. Kobayashi, N.; Shimada, K.; Taki, H.; Sakamoto, Y.; Kamachi, S. Radioimmunoassay method for the determination of 22- oxacalcitriol, a novel analog of 1 alpha,25-dihydroxyvitamin D3 having valuable clinical potency, in rat and human plasma. Biol. Pharm. Bull., 1995, 18(3), 382-387
123. Saito, T.; Okamoto, R.; Haritunians, T.; O'Kelly, J.; Uskokovic, M.; Maehr, H.; Marczak, S.; Jankowski, P.; Badr, R.; Koeffler, H. P. Novel Gemini vitamin D(3) analogs have potent antitumor activity. J. Steroid Biochem. Mol. Biol., 2008, 112, (1-3), 151-156
124. Lee, H. J.; Liu, H.; Goodman, C.; Ji, Y.; Maehr, H.; Uskokovic, M.; Notterman, D.; Reiss, M.; Suh, N. Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer. Biochem. Pharmacol., 2006, 72(3), 332-343 (Pubitemid 43975086)
125. Hansen, C. M.; Maenpaa, P. H. EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells. Biochem. Pharmacol., 1997, 54(11), 1173-1179
126. Lu, L.; Qiu, J.; Liu, S.; Luo, W. Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57. Mol. Cancer Ther., 2008, 7(5), 1268-1274
127. Colston, K. W.; Chander, S. K.; Mackay, A. G.; Coombes, R. C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol., 1992, 44(4), 693-702.
128. VanWeelden, K.; Flanagan, L.; Binderup, L.; Tenniswood, M.; Welsh, J. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology, 1998, 139(4), 2102-2110 (Pubitemid 28513874)
129. Sundaram, S.; Beckman, M. J.; Bajwa, A.; Wei, J.; Smith, K. M.; Posner, G. H.; Gewirtz, D. A. QW-1624F2-2, a synthetic analogue of 1,25-dihydroxyvitamin D3, enhances the response to other deltanoids and suppresses the invasiveness of human metastatic breast tumor cells. Mol. Cancer Ther., 2006, 5(11), 2806-2814
130. Posner, G. H. Low-calcemic vitamin D analogs (deltanoids) for human cancer prevention. J. Nutr., 2002, 132(12), 3802S-3803S.
131. Brandi, L. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol - an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Dan. Med. Bull., 2008, 55(4), 186-210.
132. Drueke, T. B. Medical management of secondary hyperparathyroidism in uremia. Am. J. Med. Sci., 1999, 317(6), 383-389 (Pubitemid 30349687)
133. Agoston, E. S.; Hatcher, M. A.; Kensler, T. W.; Posner, G. H. Vitamin D analogs as anti-carcinogenic agents. Anticancer Agents Med. Chem., 2006, 6(1), 53-71.
134. Reddy, C. D.; Patti, R.; Guttapalli, A.; Maris, J. M.; Yanamandra, N.; Rachamallu, A.; Sutton, L. N.; Phillips, P. C.; Posner, G. H. Anticancer effects of the novel 1alpha, 25-dihydroxyvitamin D3 hybrid analog QW1624F2-2 in human neuroblastoma. J. Cell Biochem., 2006, 97(1), 198-206.
135. Yee, Y. K.; Chintalacharuvu, S. R.; Lu, J.; Nagpal, S. Vitamin D receptor modulators for inflammation and cancer. Mini. Rev. Med. Chem., 2005, 5(8), 761-778 (Pubitemid 41051899)
136. Schuster, I.; Egger, H.; Reddy, G. S.; Vorisek, G. Combination of vitamin D metabolites with selective inhibitors of vitamin D metabolism. Recent Results Cancer Res., 2003, 164, 169-188
137. Kahraman, M.; Sinishtaj, S.; Dolan, P. M.; Kensler, T. W.; Peleg, S.; Saha, U.; Chuang, S. S.; Bernstein, G.; Korczak, B.; Posner, G. H. Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxyvitamin D(3). J. Med. Chem., 2004, 47(27), 6854-6863